Nafamostat for Prophylaxis against Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Compared with Gabexate
Background/AimsThe protease inhibitors, nafamostat and gabexate, have been used to prevent pancreatitis related to endoscopic retrograde cholangiopancreatography (ERCP). In vitro, nafamostat inhibits the pancreatic protease activities 10-100 times more potently than gabexate. We evaluated the effica...
| Published in: | Gut and Liver |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Gastroenterology Council for Gut and Liver
2009-09-01
|
| Subjects: | |
| Online Access: | http://gutnliver.org/journal/view.html?doi=10.5009/gnl.2009.3.3.205 |